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Abstract: This study aimed to evaluate the therapeutic effect of fraxinellone on inflammatory arthritis
and identify the underlying mechanisms. Fraxinellone (7.5 mg/kg) or a vehicle control was injected
into mice with collagen-induced arthritis (CIA). The severity of arthritis was evaluated clinically
and histologically. The differentiation of CD4+ T cells and CD19+ B cells was investigated in
the presence of fraxinellone. Osteoclastogenesis after fraxinellone treatment was evaluated by
staining with tartrate-resistant acid phosphatase (TRAP) and by measuring the mRNA levels of
osteoclastogenesis-related genes. Fraxinellone attenuated the clinical and histologic features of
inflammatory arthritis in CIA mice. Fraxinellone suppressed the production of interleukin-17
and the expression of RAR-related orphan receptor γ t and phospho-signal transducer and activator
of transcription 3 in CD4+ T cells. CD19+ B cells showed lower expression of activation-induced
cytidine deaminase and B lymphocyte-induced maturation protein-1 after treatment with fraxinellone.
The formation of TRAP-positive cells and the expression of osteoclastogenesis-related markers were
reduced in the presence of fraxinellone. Inhibition of interleukin-17 and osteoclastogenesis was also
observed in experiments using human peripheral mononuclear cells. Fraxinellone alleviated synovial
inflammation and osteoclastogenesis in mice. The therapeutic effect of fraxinellone was associated
with the inhibition of cellular differentiation and activation. The data suggests that fraxinellone could
be a novel treatment for inflammatory arthritis, including rheumatoid arthritis.
Keywords: fraxinellone; collagen-induced arthritis; rheumatoid arthritis; inflammatory
arthritis; osteoclastogenesis
1. Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammatory
polyarthritis that lead to joint destruction and functional disability. The pathogenesis of RA still remains
to be determined, but the interplay between various immune cells would be critical in the development
and progression of RA [1]. The pathologic roles of T cells have been extensively studied, and the
inflammatory subset of T cells producing interleukin (IL)-17 (Th17 cells) is considered to play a key
role in the pathogenesis of inflammatory arthritis [2]. IL-17 stimulates RA synoviocytes to produce
IL-6, which promotes the production of proinflammatory mediators, such as IL-1β, tumor necrosis
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factor-alpha (TNF-α), and matrix metalloproteinase, and accelerates synovial inflammation and bone
destruction. IL-6 also induces reciprocal differentiation of CD4+ T cells into Th17 cells. IL-17 induces
the expression of receptor activator of nuclear factor-κB (RANK) ligand (RANKL), and accelerates
erosion of bone. In addition, B cells producing specific autoantibodies contribute to the pathogenesis of
RA. Although the pathologic role of B cells is unclear, targeted-therapy-blocking B cells has long-lasting
therapeutic effects in patients with RA [3,4]. Treatment of RA aims to suppress the inflammatory
response provoked by these immune cells, and thus reduce the synovitis and osteoclastogenesis [5].
Recent advances in RA treatment have generated greater therapeutic opportunity, which has
led to improved clinical outcomes in RA patients. Drug therapy in RA aims to reach and maintain
a disease remission state via treatment with disease modifying antirheumatic drugs (DMARDs).
However, some patients still show inadequate response to DMARDs, or the use of DMARDs is often
limited due to comorbidities and drug complications. Thus, there are efforts to investigate novel
therapeutic agents to treat RA in an effective and safe way. For development of new drugs, traditional
medicine could be a promising approach.
The root bark of Dictamnus dasycarpus, a plant widely distributed throughout Korea and China,
is a traditional herb used to treat inflammatory conditions. There have been recent efforts to identify
the active components of D. dasycarpus, and the identified compounds have included dictamdiol,
rutevin, limonoid, fraxinellone, fraxinellonone, obacunone, and dictamine [6,7]. Among these
constituents, fraxinellone is suggested to have anti-inflammatory and neuroprotective effects [8–14].
Recent studies have suggested that fraxinellone has a potential therapeutic effect in animal models
with inflammatory diseases. Fraxinellone demonstrated therapeutic efficacy in mice with experimental
colitis, and T cell-dependent hepatitis [13,15]. In an allergy murine model, treatment with D. dasycarpus
extract was also effective [16].
This study aimed to evaluate the therapeutic effect of fraxinellone in mice with inflammatory
arthritis and identify the underlying mechanisms that contribute to alleviating inflammatory arthritis.
We compared clinical arthritis between collagen-induced arthritis (CIA) mice treated with fraxinellone
and a vehicle control, and investigated the inhibitory effects of fraxinellone on inflammatory immune
cell functions.
2. Results
2.1. Fraxinellone Alleviates Inflammatory Arthritis in CIA Mice
Either fraxinellone (7.5 mg/kg) or a vehicle control was administered intraperitoneally into
CIA mice in order to evaluate the therapeutic effects of fraxinellone on inflammatory arthritis.
The arthritis score was not significantly different between fraxinellone-treated mice and control
CIA mice until five weeks after primary immunization. After five weeks, fraxinellone-treated CIA
mice showed a mild form of inflammatory arthritis when compared to control CIA mice (Figure 1A).
The difference in arthritis severity between CIA mice treated with fraxinellone or the vehicle control
was maintained during the evaluation period. The tarsal joints of control CIA mice showed destruction
of articular structures and inflammatory cell infiltration, whereas the joints of fraxinellone-treated
CIA mice showed retained structure (Figure 1B). The serum level of immunoglobulin G (IgG)
in fraxinellone-treated mice was also decreased (Figure 1C). To evaluate the effect of fraxinellone
on cytokine production, splenocytes of CIA mice treated with fraxinellone or the vehicle control were
stimulated with anti-cluster of differentiation (CD) 3 antibodies. The levels of TNF-α and interferon-γ
(IFN-γ) in the culture supernatant were lower in the fraxinellone-treated group as compared to the
control group, although the difference was not statistically significant (Figure 1D).
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Figure 1. Fraxinellone attenuates inflammatory arthritis in mice. (A) Mice with collagen-induced 
arthritis (CIA) were treated with fraxinellone (7.5 mg/kg) or the vehicle control (n = 10 in each group). 
The arthritic score was defined as the sum of the scores of three paws (excluding the boosted paw); 
scores ranged from 0 to 12. (B) Tarsal joint tissues of CIA mice treated with fraxinellone or the control 
vehicle were stained with haematoxylin & eosin. The scale bars at the bottom right of the images 
indicate 200 μm. (C) Serum levels of IgG1 and IgG2a of CIA mice were determined using an enzyme-
linked immunosorbent assay (ELISA). (D) Splenocytes of CIA mice were stimulated with or without 
anti-CD3 antibodies. The level of TNF-α and IFN-γ in culture media were measured by ELISA. Data 
are expressed as mean ± standard error of the mean (SEM). IgG1, immunoglobulin G1; IgG2a, 
immunoglobulin G2a; Frx, fraxinellone; TNF-α, tumor necrosis factor-α; IFN-γ, interferon-γ; Nil, no 
treatment; aCD3, stimulation with anti-CD3 antibodies; NS, not significant; ** p < 0.01; *** p < 0.001. 
2.2. Fraxinellone Suppresses a Th17 Cell-Related Pathway 
Since Th17 cells play a critical role in the pathogenesis of RA, we investigated the effect of 
fraxinellone on Th17 differentiation in vitro. To determine the dose of fraxinellone in a cell-based 
assay, an in vitro cytotoxicity assay was performed (Figure 2A). More than 80% of cells were viable 
until the concentration of fraxinellone was increased to 80 μM. Based on the cytotoxicity assay, CD4+ 
T cells isolated from murine spleens were cultured under Th17 differentiation conditions with a 
fraxinellone dose between 30 and 50 μM (Figure 2B). The proportion of CD4+IL-17+ cells was reduced 
by treatment with fraxinellone in a dose-dependent manner, however the difference was not 
statistically significant. 
The expression of IL-17 and RAR-related orphan receptor gamma t (RORγt) in CD4+ T cells was also 
evaluated in the absence or presence of 40 μM of fraxinellone. Although we did not observe a 
statistically significant inhibitory effect of fraxinellone on Th17 differentiation, the expression of IL-
17 and RORγt was markedly decreased by treatment with fraxinellone (Figure 2C). The expression 
of signal transducer and activator of transcription 3 (STAT3), one of the most important transcription 
factors in Th17 differentiation, was also investigated using Western blot analysis of T cells cultured 
with IL-6. The expression of phospho-STAT3 was suppressed in the presence of fraxinellone, 
suggesting that the signaling pathway associated with Th17 differentiation is downregulated by 
fraxinellone (Figure 2D). 
Figure 1. Fraxinellone attenuates inflammatory arthritis in mice. (A) Mice with collagen-induced
arthritis (CIA) were treated with fraxinellone (7.5 mg/kg) or the vehicle control (n = 10 in each group).
The arthritic score was defined as the sum of the scores of three paws (excluding the boosted paw);
scores ranged from 0 to 12. (B) Tarsal joint tissues of CIA mice treated with fraxinellone or the control
vehicle were stained with haematoxylin & eosin. The scale bars at the bottom right of the images indicate
200 µm. (C) Serum levels of IgG1 and IgG2a of CIA mice were determined using an enzyme-linked
immunosorbent assay (ELISA). (D) Splenocytes of CIA mice were stimulated with or without anti-CD3
antibodies. The level of TNF-α and IFN-γ in culture media were measured by ELISA. Data are expressed
as mean ± standard error of the mean (SEM). IgG1, immunoglobulin G1; IgG2a, immunoglobulin
G2a; Frx, fraxinellone; TNF-α, tumor necrosis factor-α; IFN-γ, interferon-γ; Nil, no treatment; aCD3,
stimulation with anti-CD3 antibodies; NS, not significant; ** p < 0.01; *** p < 0.001.
2.2. Fraxinellone Suppresses a Th17 Cell-Related Pathway
Since Th17 cells play a critical role in the pathogenesis of RA, we investigated the effect of
fraxinellone on Th17 differentiation in vitro. To determine the dose of fraxinellone in a cell-based assay,
an in vitro cytotoxicity assay was performed (Figure 2A). More than 80% of cells were viable until the
concentration of fraxinellone was increased to 80 µM. Based on the cytotoxicity assay, CD4+ T cells
isolated from murine spleens were cultured under Th17 differentiation conditions with a fraxinellone
dose between 30 and 50 µM (Figure 2B). The proportion of CD4+IL-17+ cells was reduced by treatment
with fraxinellone in a dose-dependent manner, however the difference was not statistically significant.
The expression of IL-17 and RAR-related orphan receptor gamma t (RORγt) in CD4+ T cells was
also evaluated in the absence or presence of 40 µM of fraxinellone. Although we did not observe
a statistically significant inhibitory effect of fraxinellone on Th17 differentiation, the expression of IL-17
and RORγt was markedly decreased by treatment with fraxinellone (Figure 2C). The expression of
signal transducer and activator of transcription 3 (STAT3), one of the most important transcription
factors in Th17 differentiation, was also investigated using Western blot analysis of T cells cultured
with IL-6. The expression of phospho-STAT3 was suppressed in the presence of fraxinellone,
suggesting that the signaling pathway associated with Th17 differentiation is downregulated by
fraxinellone (Figure 2D).
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Figure 2. Fraxinellone inhibits Th17 differentiation. (A) Cell viability was evaluated using Cell 
Counting Kit-8 after treatment with 0, 40, and 80 μM of fraxinellone. Doses of fraxinellone with cell 
viability over 80% were considered tolerable. (B) CD4+ T cells were differentiated into Th17 cells in 
the presence of various doses of fraxinellone. The proportion of CD4+IL-17A+ cells was measured by 
flow cytometry. (C) Relative mRNA expression of IL-17 and RORγt after treatment with or without 
fraxinellone was determined by reverse transcriptase-polymerase chain reaction (RT-PCR). CD4+ T 
cells were cultured with or without fraxinellone (40 μM) under Th17-favoring conditions. Data 
represent the mean of three independent experiments ± SEM. NS, not significant; *** p < 0.001. (D) 
Expression of STAT3 in CD4+ T cells in the presence or absence of fraxinellone was evaluated using 
Western blot analysis. CD4+ T cells were stimulated with IL-6, and the expression levels of STAT3 and 
phospho-STAT3 were determined by Western blot analysis. Frx, fraxinellone; aCD3, stimulation with 
anti-CD3 antibodies; RORγt, RAR-related orphan receptor γ t; STAT3, signal transducer and activator 
of transcription 3; pSTAT3Y705, phosphor-STAT3 at Tyrosine 705; pSTAT3S727, phosphor-STAT3 at 
Serine 727. 
2.3. Fraxinellone Controls B Cell Function 
Because we observed reduced production of IgG in fraxinellone-treated CIA mice, we evaluated 
the effect of fraxinellone on immunoglobulin production and mRNA expression of CD19+ cells in 
vitro. The expression levels of B lymphocyte-induced maturation protein-1 (Blimp-1) and activation-
induced cytidine deaminase (AID), important transcription factors involved in development of germinal 
centers and antibody production, were upregulated after stimulation by lipopolysaccharides (LPS), 
but were significantly decreased by treatment with 40 μM of fraxinellone (Figure 3A,B). The 
production of immunoglobulin after LPS stimulation was also reduced by fraxinellone in a dose-
dependent manner (Figure 3C). 
Figure 2. Fraxinellone inhibits Th17 differentiation. (A) Cell viability was evaluated using ell
o ting Kit-8 after treatment with 0, 40, and 80 µM of fraxinellone. Doses of fraxinellone with
cell viability over 80% were considered tolerable. (B) CD4+ T cells were differentiated into Th17
cells in the presence of various doses of fraxinellone. The proportion of CD4+IL-17A+ cells was
measured by flow cytometry. (C) R lative mRNA expression of IL-17 and RORγt after treatment
with or without fraxinellone was determi ed by reverse transcript se-polymerase chain reaction
(RT-PCR). CD4+ T cells were cultured with or without fraxi ellone (40 µM) under Th17-favoring
conditions. Data represent the mea of hree independent experiment ± SEM. NS, not significant;
*** p < 0.001. (D) Expression of STAT3 in CD4+ T cells in th presence or absence of fraxinellone was
evaluated usi g We tern blot analysis. CD4+ T cells were stimulat d with IL-6, and the expression
levels of and phospho-STAT3 wer determined by Western blot analysis. Frx, fr xinellone;
CD3, stimulation with anti-CD3 antibo ies; RORγt, RAR-related orpha receptor γ t; STAT3, signal
transdu er and activator of transcription 3; pSTAT3Y705, phosphor-STA 3 at Tyrosine 705; p T3S727,
phosphor-STAT3 at Serine 727.
. . Fraxi ello e o tr ls ell cti
s s r r r ti f I i fraxi ell -tr t I i , e al t
t ff t of fraxinellone on im unoglobulin production a d mRNA expression of CD19+ cells in vitro.
The expr ssion levels of B lymphoc te-induced maturation protein-1 (Blimp-1) and activation-induced
cytidine deaminase (AID), important transcription factors involved in development of g rminal centers
and antibody production, were upregulated after stimulation by lip pol saccharides (LPS), but were
significantly decreased by treatment with 40 µM of fraxinell ne (Figure 3A,B). Th production
of immunoglobulin after LPS stimulation was ls reduced by fraxinellone in a d se-dependent
man er (Figure 3C).
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Figure 3. Fraxinellone inhibits B cell maturation. (A,B) CD19+ B cells were activated by 
lipopolysaccharide. After treatment with or without fraxinellone (40 μM), the relative expression 
levels of AID and Blimp-1 in CD19+ B cells were determined with RT-PCR. (C) The level of 
immunoglobulin G in the culture supernatant was measured using ELISA in the presence of 
fraxinellone at doses of 0–40 μM. In all culture conditions, CD19+ B cells were stimulated by 
lipopolysaccharide. Data represent the mean of three independent experiments ± SEM. Nil, no 
stimulation; LPS, stimulation with lipopolysaccharide; Frx, fraxinellone; AID, activation-induced 
cytidine deaminase; Blimp-1, B lymphocyte-induced maturation protein-1; IgG, immunoglobulin G; 
* p < 0.05; ** p < 0.01; *** p < 0.001. 
2.4. Fraxinellone Inhibits Murine Osteoclastogenesis 
CIA mice treated with fraxinellone showed a significant improvement in bone erosion as 
compared to control CIA mice. Because the production of IL-17, which is responsible for 
osteoclastogenesis, was inhibited by fraxinellone, we hypothesized that fraxinellone would inhibit 
osteoclastogenesis. To confirm the inhibitory effect of fraxinellone on osteoclastogenesis, murine 
bone marrow-derived monocytes were cultured with macrophage-colony stimulating factor (M-CSF) 
and RANKL, in the presence or absence of fraxinellone. 
Monocyte cultures with various doses of fraxinellone between 10 to 40 μM showed a dose-
dependent inhibition of osteoclast formation, which was determined by tartrate-resistant acid 
phosphatase (TRAP) staining (Figure 4A). The expression levels of osteoclastogenesis-related 
markers, such as TRAP, cathepsin K, and matrix metalloproteinase 9 (MMP9), were significantly lower 
in the presence of 40 μM of fraxinellone (Figure 4B). The expression levels of other osteoclast markers, 
osteoclast-associated immunoglobulin-like receptor (OSCAR) and calcitonin receptor, were also reduced, 
although the difference was not statistically significant. 
Figure 3. Fraxinello e inhibits B cell maturation. ( , ) 19+ cells were activated by
lipopolysac haride. After treatment with or without fraxinellone (40 µM), the relative expression
levels of AID and Blimp-1 in CD19+ B cells were determined with RT-PCR. (C) The level of
im unoglobulin G in the culture sup rnatant was measured using ELISA in the prese ce of fraxin llone
at doses of 0–40 µM. In all culture conditions, CD19+ B cells were stimulated by lipopolysaccharide.
Data represent the mean of three independent xperiments± SEM. Nil, o stimulatio ; LPS, stimulatio
wi h lipopolysacchar de; Frx, fraxine lone; AID, activation-induced cytidine deaminase; Blimp-1,
B l mphocyte-induc d maturation protein-1; IgG, immunoglobulin G; * p < 0.05; ** p < 0.01; *** p < 0.001.
2.4. Fraxinellone Inhibits Murine Osteoclastogenesis
CIA mice treated with fraxinellone showed a significant improvement in bone erosion as
compared to control CIA mice. Because the production of IL-17, which is responsible for
osteoclastogenesis, was inhibited by fraxinellone, we hypothesized that fraxinellone would inhibit
osteoclastogenesis. To confirm the inhibitory effect of fraxinellone on osteoclastogenesis, murine
bone marrow-derived monocytes were cultured with macrophage-colony stimulating factor (M-CSF)
and RANKL, in the presence or absence of fraxinellone.
Monocyte cultures with various doses of fraxinellone between 10 to 40 µM showed
a dose-dependent inhibition of osteoclast formation, which was determined by tartrate-resistant
acid phosphatase (TRAP) staining (Figure 4A). The expression levels of osteoclastogenesis-related
markers, such as TRAP, cathepsin K, and matrix metalloproteinase 9 (MMP9), were significantly lower in
the presence of 40 µM of fraxinellone (Figure 4B). The expression levels of other osteoclast markers,
osteoclast-associated immunoglobulin-like receptor (OSCAR) and calcitonin receptor, were also reduced,
although the difference was not statistically significant.
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Figure 4. Fraxinellone suppresses murine osteoclastogenesis. (A) Murine monocytes obtained from 
the femur and tibia were cultured with M-CSF and RANKL to induce osteoclatogenesis. TRAP-
positive multinucleated cells were counted in the culture dishes at various doses of fraxinellone 
(original magnification x100). (B) The relative mRNA levels of osteoclastogenesis-related markers, 
such as TRAP, OSCAR, Cathepsin K, CTR, and MMP9, were evaluated using RT-PCR. Data represent 
the mean of three independent experiments ± SEM. M-CSF, macrophage-colony stimulating factor; 
RANKL, receptor activator of nuclear factor-κB ligand; Frx, fraxinellone; TRAP, tartrate-resistant acid 
phosphatase; OSCAR, osteoclast-associated receptor; CTR, calcitonin receptor; MMP9, matrix 
metalloproteinase 9; M, culture with M-CSF; R, culture with M-CSF and RANKL; R + Frx, culture with 
M-CSF, RANKL, and fraxinellone; NS, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001. 
2.5. Fraxinellone Inhibits Th17 Differentiation and Osteoclastogenesis in Human 
Based on the results from CIA mice, the inhibitory effects on Th17 differentiation and 
osteoclastogenesis were evaluated using peripheral blood mononuclear cells obtained from healthy 
controls. 
Human CD4+ T cells were cultured under Th17 differentiation condition with or without 40 μM 
of fraxinellone. Consistent with results from the animal experiments, the proportion of Th17 cells was 
not significantly different after treatment with fraxinellone, but the production of IL-17 was 
suppressed in the presence of fraxinellone (Figure 5A). 
Fraxinellone also inhibited osteoclast differentiation from human peripheral blood mononuclear 
cells. Multinucleated cells stained with TRAP were significantly reduced in the presence of 
fraxinellone (Figure 5B). Fraxinellone also reduced the mRNA expression of osteoclastogenesis-
Figure 4. Fraxinellone suppresses murine osteoclastogenesis. (A) Murine monocytes obtained from the
femur and tibia were cultured with M-CSF and RANKL to induce osteoclatogenesis. TRAP-positive
multinucleated cells were counted in the culture dishes at various doses of fraxinellone (original
magnification x100). (B) The relative mRNA levels of osteoclastogenesis-related markers, such as TRAP,
OSCAR, Cathepsin K, CTR, and MMP9, were evaluated using RT-PCR. Data represent the mean of three
independent experiments ± SEM. M-CSF, macrophage-colony stimulating factor; RANKL, receptor
activator of nuclear factor-κB ligand; Frx, fraxin ll ne; AP, tartrate-resistant acid phosphatase;
OSCAR, osteoclast-associated r ceptor; TR, calcitonin receptor; MMP9, matrix metalloproteinase 9;
M, culture with M-CSF; R, culture with M-CSF and RANKL; R + Frx, culture with M-CSF, RANKL,
and fraxinellone; NS, not significant; * p < 0.05; ** p < 0.01; *** p < 0.001.
2.5. Fraxinellone I hibits Th17 Differentiation and Osteoclastogenesis in Human
Based on the results from CIA mice, the inhibitory effects on Th17 differentiation and
osteoclastogenesis were evaluated using peripheral blood mononuclear cells obtained from
healthy controls.
Huma CD4+ T cells were cultured under T 17 diff re tiation condition with r without 40 µM
of fraxinellon . Consistent with results from the animal experiments, the proportion of Th17 cells was
not significantly different after treatment with fraxinellone, but the production of IL-17 was suppressed
in the presence of fraxinellone (Figure 5A).
Fraxinellone also inhibited osteoclast differentiation from human peripheral blood mononuclear
cells. Multinucleated cells stained with TRAP were significantly reduced in the presence of fraxinellone
(Figure 5B). Fraxinellone also reduced the mRNA expression of osteoclastogenesis-related markers:
MMP9, RANK, cathepsin K, integrin β3, and nuclear factor of activated T-cells 1 (NFATc1) (Figure 5C).
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Figure 5. Fraxinellone regulates Th17 differentiation and osteoclastogenesis in human monocytes.
(A) CD4+ T cells isolated from human peripheral blood mononuclear cells were cultured under
Th17 differentiation conditions. After treatment with or without fraxinellone, the proportion of
CD4+IL17+ T cells and IL-17 production were determined using flow cytometry and enzyme-linked
immunosorbent assays, respectively. (B) Human peripheral blood mononuclear cells were cultured
with M-CSF and RANKL to induce osteoclastogenesis. The number of TRAP-positive multinucleated
cells was counted in the culture dishes with or without fraxinellone (40 µM) (original magnification
×100). (C) The expression levels of osteoclastogenesis-related markers, MMP9, RANK, Cathepsin K,
integrin β3, and NFATc1 were determined using RT-PCR in the absence or presence of fraxinellone
(40 µM). Data represent the mean of three independent experiments ± SEM. Frx, fraxinellone;
M-CSF, macrophage-colony stimulating factor; RANKL, receptor activator of nuclear factor-κB ligand;
TRAP, tartrate-resistant acid phosphatase; MMP9, matrix metalloproteinase 9; RANK, receptor activator
of nuclear factor-κB; NFATc1, nuclear factor of activated T-cells 1; R, culture with M-CSF and RANKL;
R + Frx, culture with M-CSF, RANKL, and fraxinellone; NS, not significant; * p < 0.05; *** p < 0.001.
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3. Discussion
Fraxinellone is a natural compound isolated from a widely distributed plant in Korea. In this study,
fraxinellone showed a therapeutic effect on inflammatory arthritis. Fraxinellone alleviates synovial
inflammation and osteoclast formation in CIA mice through inhibition of immune cells. This inhibitory
effect was reproduced with in vitro experiments using human peripheral blood mononuclear cells.
To the best of our knowledge, this is the first report that suggests an antiarthritic role of fraxinellone.
The root bark of D. dasycarpus has been a traditional herb used in the inflammatory conditions,
such as colds, rheumatism, and jaundice. Recently, there have been efforts to delineate the underlying
mechanisms of traditional medicines, and the anti-inflammatory effect of an active component of
D. dasycarpus, fraxinellone, was evaluated in animal models with inflammatory diseases [12,13,15–17].
Previous research studies have proposed several mechanisms to explain the anti-inflammatory effects
of fraxinellone.
In this study, we observed the inhibition of Th17 cell differentiation by fraxinellone. The expression
levels of IL-17 and Th17 cell-related transcription factors were markedly reduced in the presence of
fraxinellone. Although the proportion of Th17 cells showed no statistically significant difference
between treatment with or without fraxinellone, there was a dose-dependent reduction. The critical
transcription factors for Th17 differentiation, RORγt and phospho-STAT3, were downregulated by
fraxinellone, which would explain inhibition of Th17 cells. A previous study had also suggested an
inhibitory effect of fraxinellone on STAT1/3 expression in murine microglial cells [11]. Fraxinellone
suppressed the activation of STAT1/3 signalling pathway triggered by viral components, leading to
inhibition of inducible nitric oxide synthetase expression. Given that Th17 cells have a critical role
in the pathogenesis of autoimmune diseases [2], fraxinellone may have a therapeutic effect in other
inflammatory diseases.
However, inhibition of IL-17 does not guarantee the therapeutic effect in RA. Although the
previous research provided a robust evidence for the therapeutic effect of inhibiting Th17 cell
differentiation in animal studies, anti-IL-17 therapy failed to show the consistent therapeutic benefit in
patients with active RA [18]. It is difficult to explain what makes this discrepancy. One study suggested
that the highly variable expression of IL-17 in synovium between individual patients with RA could
be responsible for inadequate response to anti-IL-17 therapy in subsets of patients [19]. Other possible
explanations may be whether the drug targets Th17 cells or only IL-17. The previous research
have suggested that IL-17 is not a potent inducer of inflammation by itself [20]. IL-17 accelerates
the inflammatory response, in combination with other cytokines, such as TNF-α and IL-22 [21].
Th17 cells produce IL-22 as well as IL-17, and the synergistic activity of these cytokines might enhance
the inflammatory reaction in RA. Given the importance of Th17 cells in the pathogenesis of RA,
further investigations should be performed to elucidate the mechanisms underlying the inconsistent
effect of anti-IL-17 therapy in RA patients.
Fraxinellone also inhibited the function of B cells in vivo and in vitro. Consistent with the
lower serum levels of IgG in fraxinellone-treated CIA mice as compared to control CIA mice,
in vitro experiments also showed fraxinellone-dependent suppression of IgG production from CD19+
B cells. The expression levels of critical transcription factors for B cell maturation were markedly
downregulated in the presence of fraxinellone. AID and Blimp-1 play a key role for switch
recombination/hypermutation in B cells and differentiation into plasma cells, respectively [22,23].
Thus, inhibition of AID and Blimp-1 in B cells would reduce the production of autoantibodies in
immune-mediated diseases. To our knowledge, there have been no data on the suppression of
B cells by fraxinellone. Considering that B cell-depleting therapy is effective for the treatment of RA,
the inhibition of B-cell function would be a credible mechanism for the therapeutic effect of fraxinellone
on inflammatory arthritis.
Previous studies have suggested that there is a fraxinellone-dependent inhibitory effect on
macrophages under inflammatory conditions. Fraxinellone significantly reduced the expression
of inducible nitric oxide synthetase and cyclooxygenase-2 through inhibition of nuclear factor-κB
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(NF-κB) in LPS-treated RAW264.7 cells. THP-1 cells and mouse primary peritoneal cells also showed
downregulated expression of NF-κB signalling after treatment with fraxinellone [13]. NF-κB is
a critical transcription factor that induces osteoclastogenesis [24,25]. Consistent with those previous
observations, we observed the inhibition of osteoclastogenesis in the presence of fraxinellone.
Because the therapeutic goal in RA treatment is to prevent joint destruction and to preserve joint
function, the anti-osteoclastogenic effect of fraxinellone would provide better clinical outcomes in
RA treatment.
Interestingly, fraxinellone seems to have an anti-inflammatory effect through inhibition of cellular
differentiation or activation. In an animal model with T-cell-dependent hepatitis, fraxinellone induced
apoptosis of activated CD4+ T cells in vivo and in vitro and inhibited the activation and infiltration
of CD4+ T cells to the liver [15]. In a murine allergy model, the extract of D. dasycarpus significantly
inhibited histamine release from activated mast cells [16]. Fraxinellone also controlled the activation of
macrophages in mice with experimental colitis. The production of inflammatory mediators including
IL-1β and nitric oxide from macrophages was significantly reduced by fraxinellone [13]. It is unclear
whether the inhibitory effect of fraxinellone is limited to proinflammatory immune cells, or fraxinellone
globally suppresses cellular differentiation and activation. Because drug safety is one of the most
important issues for drug development, further investigation would be required to clarify the side
effects of fraxinellone on normal cells.
In conclusion, fraxinellone has an inhibitory effect on synovial inflammation and
osteoclastogenesis in mice with inflammatory arthritis. Fraxinellone could have a therapeutic effect
through inhibition of cellular differentiation and activation. Although the safety profile should be
determined, fraxinellone could be a novel treatment in inflammatory arthritis, such as RA.
4. Materials and Methods
4.1. Induction of CIA and Treatment with Fraxinellone
Male DBA/1J mice at 7 weeks of age (purchased from Charles River Laboratories, Yokohama,
Japan) were injected intradermally at the base of the tail with 100 µg of type II collagen (CII)
in complete Freund’s adjuvant (Chondrex, Redmond, WA, USA). Two weeks later, the mice were
boosted in one hind footpad with 100 µg of CII emulsified in incomplete Freund’s adjuvant (Chondrex).
The mice received intraperitoneal injection with either fraxinellone (7.5 mg/kg) or vehicle control
(saline) three times per week beginning on day 14 after primary immunization. All procedures
involving animals were in accordance with the Laboratory Animals Welfare Act, the Guide for the
Care and Use of Laboratory Animals, and the Guidelines and Policies for Rodent Experimentation
provided by the Institutional Animal Care and Use Committee of the Catholic University of Korea
School of Medicine (CUMC-2014-0074-02, approved on 15 May 2014).
4.2. Assessment of Arthritis
The severity of inflammation was determined on a graded scale of 0 to 4 by three independent
investigators as described previously [26]: 0 = no evidence of erythema and swelling; 1 = erythema and
mild swelling confined to the mid-foot (tarsal) or ankle joint; 2 = erythema and mild swelling extending
from the ankle to the mid-foot; 3 = erythema and moderate swelling extending from the ankle to
the metatarsal joints; 4 = erythema and severe swelling encompassing the ankle, foot, and digits.
The arthritic score was expressed as the sum of the scores from three limbs, excluding the boosted paw.
Thus, the highest possible score was 12 points. Clinical arthritis was evaluated three times per week
for eight weeks after primary immunization in order to investigate the effects of fraxinellone on CIA.
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4.3. Histological Evaluation
Joint tissues of CIA mice were fixed in 10% paraformaldehyde, decalcified in Calci-Clear Rapid
bone decalcifier (National Diagnostics, Atlanta, GA, USA), and embedded in paraffin. Tissue sections
with 7-µm thickness were prepared and stained with hematoxylin and eosin (H&E).
4.4. Analysis of Immunoglobulin G
Blood drawn from the orbital sinuses of mice was stored at −20 ◦C until use. The serum samples
were diluted to 1:100,000 or 1:50,000 in Tris-buffered saline (pH 8.0) containing 1% bovine serum
albumin and 0.5% Tween-20 for measurement of IgG1 or IgG2a, respectively. The concentrations of
total IgG1 and IgG2a were measured using mouse IgG1 and IgG2a enzyme-linked immunosorbent
assay (ELISA) Quantitation Kits (Bethyl Laboratories, Montgomery, TX, USA), respectively. Absorbance
values were determined with an ELISA microplate reader operating at 450 nm.
4.5. Cytokine Measurement
Total splenocytes (1× 106 cells/mL/well) were stimulated with plate-bound anti-CD3 monoclonal
antibodies (0.5 µg/mL) for 3 days. The levels of TNF-α, IFN-γ and IL-17 were determined using the
DuoSet ELISA Development System (R&D Systems, Minneapolis, MN, USA).
4.6. Cytotoxicity
Total splenocytes (2× 105 cells/well) were seeded into 96-well flat-bottomed plates and stimulated
with various doses (30, 40, 50 and 80 µM) of fraxinellone for 24 h. Two hours before termination of
the culture, Cell Counting Kit-8 (Dojindo Molecular Technologies, Rockville, MD, USA) solution was
added to the culture in order to evaluate the absorbance at 450 nm via a microplate reader.
4.7. Culture of CD4+ T Cells and CD19+ B Cells
Murine CD4+ T cells and CD19+ B cells were purified from spleens, and human CD4+ T cells were
isolated from peripheral blood using a MACS isolation kit (Miltenyi Biotec Inc., Bergisch Gladbach,
Germany) according to the manufacturer’s instructions. Protocols involving human samples were
approved by the Institutional Review Board of Seoul St. Mary’s Hospital (KC15TISI0059, Approved on
15 March 2016). Cells were cultured in RPMI1640 media (Gibco, Grand Island, NY, USA) containing
10% fetal bovine serum (FBS).
Human or murine CD4+ T cells were treated with plate-bound anti-CD3 (0.5 µg/mL)
and anti-CD28 (1 µg/mL) (BD PharMingen, San Diego, CA, USA). To evaluate the effect of
fraxinellone on Th17 differentiation, CD4+ T cells were cultured with recombinant transforming growth
factor-β (2 ng/mL) (PeproTech, Rocky Hill, NJ, USA), IL-6 (20 ng/mL), anti-interferon-γ (2 µg/mL),
and anti-IL-4 (2 µg/mL) (R&D Systems) in the absence or presence of fraxinellone. Three days
later, RNA was extracted for evaluation of mRNA expression, and culture media was obtained for
measurement of IL-17.
The effect of fraxinellone on B cells was investigated with CD19+ B cells stimulated with 1 µg/mL
LPS (Sigma-Aldrich, St. Louis, MO, USA) in the presence of fraxinellone. RNA and culture media
were obtained for analysis after a 4-day culture.
4.8. Flow Cytometry
For intracellular detection of IL-17, CD4+ T cells were incubated with 25 ng/mL phorbol
12-myristate 13-acetate (PMA), 250 ng/mL ionomycin (Sigma-Aldrich), and monensin-containing
GolgiStop (BD Biosciences, San Jose, CA, USA) for 4 h. The harvested cells were stained
with PerCP-conjugated anti-CD4 antibodies (Biolegend, San Diego, CA, USA). After fixation
with fixation/permeabilization solution, the cells were stained with 0.125 µg FITC-conjugated
anti-IL-17 antibodies (eBioscience, San Diego, CA, USA) to determine the population of Th17 cells.
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All analyses were performed using a BD LSRII fortessa (BD Biosciences) and FACS DIVA version 10.0
(BD Biosciences).
4.9. Real-Time Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA). PCR amplification and
analyses were performed with a LightCycler 480 II instrument (Roche Life Science, Penzberg, Germany)
according to the manufacturer’s instructions. LightCycler 480 SYBR Green I Master Mix (Roche Life
Science) was used to develop all reactions. The primers for RT-PCR are given in Table 1. All mRNA
expression levels were normalized to β-actin mRNA levels.
Table 1. Primer sequences for real-time RT-PCR.
Gene Sense (5′–3′) Anti-Sense (5′–3′)
Mouse
IL-17 CCTCAAAGCTCAGCGTGTCC GAGCTCACTTTTGCGCCAAG
RORγt TGTCCTGGGCTACCCTACTG GTGCAGGAGTAGGCCACATT
Blimp-1 CTGTCAGAACGGGATGAACA TGGGGACACTCTTTGGGTAG
AID CGTGGTGAAGAGGAGAGATAGTG CAGTCTGAGATGTAGCGTAGGAA
TRAP TCCTGGCTCAAAAAGCAGTT ACATAGCCCACACCGTTCTC
OSCAR CCTAGCCTCATACCCCCAG CAAACCGCCAGGCAGATTG
Cathepsin K CAGCAGAGGTGTGTACTATG GCGTTGTTCTTACTTCGAGC
CTR CGGACTTTGACACAGCAGAA AGCAGCAATCGACAAGGAGT
MMP9 CTGTCCAGACCAAGGGTACAGCCT GAGGTATAGTGGGACACATAGTGG
β-Actin GAAATCGTGCGTGACATCAAAG TGTAGTTTCATGGATGCCACAG
Human
MMP9 TGGGGGGCAACTCGGC GGAATGATCTAAGCCCAG
Cathepsin K TGAGGCTTCTCTTGGTGTCCATAC AAAGGGTGTCATTACTGCGGG
Integrin β3 GCAATGGGACCTTTGAGTGT GTGGCAGACACATTGACCAC
RANK GCTCTAACAAATGTGAACCA GCCTTGCCTGTATCACAAAC
NFATc1 GCATCACAGGGAAGACCGTGTC GAAGTTCAATGTCGGAGTTTCTGAG
β-actin GGACTTCGAGCAAGAGATGG TGTGTTGGGGTACAGGTCTTTG
IL-17, interleukin-17; RORγt, RAR-related orphan receptor γ t; Blimp-1, B lymphocyte-induced
maturation protein-1; AID, activation-induced cytidine deaminase; TRAP, tartrate resistant acid
phosphatase; OSCAR, osteoclast-associated immunoglobulin-like receptor; CTR, calcitonin receptor;
MMP9, matrix metalloproteinase 9; RANK, receptor activator of nuclear factor-κB; NFATc1, nuclear factor
of activated T-cells 1.
4.10. Western Blot Analysis
Murine splenocytes were treated with IL-6 (20 ng/mL), with or without fraxinellone for
30 min. At the given time, total cellular proteins from cells were extracted using RIPA buffer
containing Halt Protease and Phosphatase Inhibitor Cocktail (Thermo scientific, Waltham, MA, USA).
Polyacrylamide gel electrophoresis was performed at 100 V for 1.5 h, and proteins were transferred
to polyvynilidene fluoride membrane (Bio-Rad, Hercules, CA, USA). To evaluate protein expression,
membranes were incubated with the following antibodies: anti-STAT3, anti-phospho-STAT3Y705
(pSTAT3Y705), anti-pSTAT3S727 (Cell Signaling Technology, Danvers, MA, USA), and anti-β-actin
antibodies (Sigma-Aldrich). Subsequently, the membranes were incubated with horseradish
peroxidase-conjugated goat anti-rabbit IgG (Thermo Scientific) or goat anti-mouse IgG (Santa Cruz
Biotechnology, Dallas, TX, USA). Reactive signals were evaluated using SuperSignal® West
Pico Chemiluminescent substrate (Thermo Scientific), and the membranes were then exposed to
an Amersham Imager 600 (GE Healthcare Bioscience, Pittsburgh, PA, USA).
4.11. Osteoclastogenesis Assay
Bone marrow cells from mouse femurs and tibias and mononuclear cells isolated from peripheral
blood of healthy humans were cultured in α-minimal essential medium (α-MEM; Invitrogen)
containing antibiotics and 10% heat-inactivated FBS. To induce osteoclastogenesis, the floating murine
monocytes and adherent human monocytes were harvested and cultured with 100 ng/mL recombinant
M-CSF (R&D Systems) for 3 days. The monocytes were further stimulated with 25 ng/mL of M-CSF
and 50 ng/mL of RANKL in the absence or presence of fraxinellone. On day 2, the culture media was
Int. J. Mol. Sci. 2018, 19, 829 12 of 14
replaced with fresh medium containing the same components. After a 4-day culture, monocytes were
harvested for isolation of RNA or fixation with paraformaldehyde. The fixed cells were stained with
TRAP using a commercial kit (Sigma-Aldrich) according to the manufacturer’s instructions, omitting
the counterstaining with hematoxylin. TRAP-positive cells containing three or more nuclei were
counted under a light microscope.
4.12. Statistical Analysis
The experimental data are presented as the mean and standard error. Statistical significance was
determined using the Student’s t-test, and p-values < 0.05 were considered significant. All data were
analyzed using SAS software (v. 9.1; SAS Institute, Cary, NC, USA) and GraphPad Prism software
(v. 5.01; GraphPad, San Diego, CA, USA).
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Abbreviations
RA Rhematoid arthritis
IL Interleukin
Th17 T helper cell producing IL-17
TNF-α Tumor necrosis factor-alpha
RANK Receptor activator of nuclear factor-κB
RANKL Receptor activator of nuclear factor-κB ligand
DMARD Disease modifying anti-rheumatic drug
CIA Collagen-induced arthritis
Ig Immunoglobulin
IFN-γ Interferon-gamma
ELISA Enzyme-linked immunosorbent assay
SEM Standard error of the mean
RORγt RAR-related orphan receptor γ t
STAT3 Signal transducer and activator of transcription 3
pSTAT3 Phospho-signal transducer and activator of transcription 3
RT-PCR Reverse transcriptase-polymerase chain reaction
Blimp-1 B lymphocyte-induced maturation protein-1
AID Activation-induced cytidine deaminase
LPS Lipopolysaccharide
M-CSF Macrophage-colony stimulating factor
TRAP Tartrate resistant acid phosphatase
MMP9 Matrix metalloproteinase 9
OSCAR Osteoclast-associated immunoglobulin-like receptor
CTR Calcitonin receptor
NFATc1 Nuclear factor of activated T-cells 1.
NF-κB Nuclear factor-κB
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